Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation by Lindsten, Kristina et al.
 

 
 The Rockefeller University Press, 0021-9525/2002/04/417/11 $5.00
The Journal of Cell Biology, Volume 157, Number 3, April 29, 2002 417–427
http://www.jcb.org/cgi/doi/10.1083/jcb.200111034
 
JCB
 
Article
 
417
 
Mutant ubiquitin found in neurodegenerative 
disorders is a ubiquitin fusion degradation substrate 
that blocks proteasomal degradation
 
Kristina Lindsten,
 
1
 
 Femke M.S. de Vrij,
 
2
 
 Lisette G.G.C. Verhoef,
 
1
 
 David F. Fischer,
 
2
 
 Fred W. van Leeuwen
 
2
 
, 
Elly M. Hol,
 
2
 
 Maria G. Masucci,
 
1
 
 and Nico P. Dantuma
 
1
 
1
 
Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden
 
2
 
Graduate School for Neurosciences Amsterdam, Netherlands Institute for Brain Research, Research Group Molecular 
Misreading, 1105 AZ, Amsterdam, Netherlands
 
oss of neurons in neurodegenerative diseases is usually
preceded by the accumulation of protein deposits that
contain components of the ubiquitin/proteasome
system. Affected neurons in Alzheimer’s disease often
 
accumulate UBB
 
 
 
1
 
, a mutant ubiquitin carrying a 19–amino
acid C-terminal extension generated by a transcriptional
dinucleotide deletion. Here we show that UBB
 
 
 
1
 
 is a potent
inhibitor of ubiquitin-dependent proteolysis in neuronal
cells, and that this inhibitory activity correlates with induction
L
 
of cell cycle arrest. Surprisingly, UBB
 
 
 
1
 
 is recognized as a
ubiquitin fusion degradation (UFD) proteasome substrate
 
and ubiquitinated at Lys
 
29
 
 and Lys
 
48
 
. Full blockade of
proteolysis requires both ubiquitination sites. Moreover,
the inhibitory effect was enhanced by the introduction of
multiple UFD signals. Our ﬁndings suggest that the inhibitory
 
activity of UBB
 
 
 
1
 
 may be an important determinant of
neurotoxicity and contribute to an environment that favors
the accumulation of misfolded proteins.
 
Introduction
 
A broad array of human neurodegenerative diseases share
strikingly similar histopathological features that may hold
the key to their molecular pathogenesis (Sherman and
Goldberg, 2001). A common finding is the presence of in-
soluble proteinaceous deposits, such as the neurofibrillary
tangles and neuritic plaques of Alzheimer’s disease, the Lewy
bodies of Parkinson’s disease, and the intranuclear inclusions
of Huntington’s disease, that differ in their protein content
but invariably contain components of the ubiquitin/proteasome
system (Schwartz and Ciechanover, 1999). As this cellular
proteolytic machinery is involved in the clearance of mis-
folded proteins, this has led to the suggestion that a chronic
imbalance between their generation and processing may be
the primary cause for the formation of protein deposits (Cum-
mings et al., 1998; Sherman and Goldberg, 2001). This model
is further supported by the identification of inactivating muta-
tions in a ubiquitin ligase (Kitada et al., 1998) and a deubiqui-
tinating enzyme (Leroy et al., 1998) as the cause for rare famil-
ial forms of Parkinson’s disease as well as genetic mouse models
of neurodegeneration (Saigoh et al., 1999). Moreover, the cel-
lular toxicity correlated with nuclear inclusions can be sup-
pressed by components of the ubiquitin/proteasome system
(Fernandez-Funez et al., 2000), confirming the role of this
proteolytic pathway in the clearance of their precursors.
The demonstration that components of the ubiquitin/
proteasome system often are involved in neurodegeneration
prompted us to examine whether a general impairment of
the proteolytic machinery may contribute to the pathology.
Recently, an aberrant form of ubiquitin was found in af-
fected neurons of patients with different tauopathies such as
sporadic and familial Alzheimer’s disease, Down syndrome
(van Leeuwen et al., 1998), progressive supranuclear palsy
(Fergusson et al., 2000), Pick’s disease, frontotemporal
dementia, argyrophilic grain disease, and the polyglutamine
disorder Huntington’s disease (unpublished data), but not
in synucleinopathies, such as Lewy body disease and multi-
system atrophy (van Leeuwen et al., 1998). Ubiquitin is gen-
erated from precursor proteins consisting of tandem ubiq-
uitin moieties that are cleaved into monomeric ubiquitin by
ubiquitin C-terminal hydrolases (Wilkinson, 2000). Due to
a mechanism known as molecular misreading (van Leeuwen
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et al., 2000), a dinucleotide deletion can occur within the
mRNA encoding the ubiquitin B precursor resulting in a 
 
 
 
1
frame shift close to the C terminus of the first ubiquitin moi-
ety (van Leeuwen et al., 1998). Translation of the shifted
open reading frame results in the product UBB
 
 
 
1
 
 that com-
prises the first ubiquitin moiety with a 19–amino acid exten-
sion. Because the cleavage site of the ubiquitin C-terminal
hydrolase is absent in UBB
 
 
 
1
 
, the extension is not removed.
The aberrant C terminus prevents the activation and conju-
gation of UBB
 
 
 
1
 
,
 
 
 
but due to the unaffected lysine residues,
the mutant ubiquitin may serve as a scaffold for ligation of
wild-type ubiquitin molecules (van Leeuwen et al., 2000).
Synthetically ubiquitinated UBB
 
 
 
1
 
 was shown to inhibit
proteasomal degradation in vitro, and therefore it was hy-
pothesized that its expression in neurons may disturb ubiq-
uitin-dependent proteolysis (Lam et al., 2000). Using two
different green fluorescent protein (GFP)*-based reporters
that allow monitoring of ubiquitin-/proteasome-dependent
proteolysis in living cells (Dantuma et al., 2000b), we show
that UBB
 
 
 
1
 
 acts as a strong inhibitor of the proteasome in
vivo and induces a general accumulation of ubiquitinated
substrates and cell cycle arrest. Surprisingly, UBB
 
 
 
1
 
 is recog-
nized as a ubiquitin fusion degradation (UFD) substrate and
accordingly ubiquitinated at both Lys
 
29
 
 and Lys
 
48
 
 residues of
its ubiquitin moiety. The inhibitory capacity relies on its rec-
ognition as a UFD substrate, as substitutions of either lysine
residue releases the blockade while the inhibitory activity is
further activated by enhancement of the UFD signal.
 
Results
 
UBB
 
 
 
1 
 
inhibits the ubiquitin/proteasome 
system in living cells
 
Two previously characterized GFP-based proteasome sub-
strates carrying an N-end rule (Ub-R-GFP) or a UFD
(Ub
 
G76V
 
-GFP) degradation signal (Dantuma et al., 2000b)
were used to monitor ubiquitin-/proteasome-dependent
proteolysis in UBB
 
 
 
1
 
-expressing cells. The N-end rule deg-
radation signal triggers ubiquitination close to the N termi-
nus of the GFP reporter once the ubiquitin moiety of the
fusion is cleaved by endogenous ubiquitin C-terminal hy-
drolases (Varshavsky, 1996), whereas the UFD signal in-
cludes the N-terminal uncleavable ubiquitin moiety Ub
 
G76V
 
that serves as target for polyubiquitination (Johnson et al.,
1995). Because UBB
 
 
 
1
 
 mainly has been found in neurons,
the reporters were stably transfected in the SH-SY5Y neuro-
blastoma cell line. In addition, we used a previously charac-
terized HeLa transfectant that constitutively expresses the
Ub
 
G76V
 
-GFP reporter (Dantuma et al., 2000b). Reporter-
expressing SH-SY5Y and HeLa cells were transiently trans-
fected with FLAG-tagged ubiquitin (
 
FLAG
 
Ub) or UBB
 
 
 
1
 
, and
were analyzed in parallel for expression of these proteins
and activity of the ubiquitin/proteasome system as assessed
by accumulation of the GFP fluorescence. Microscopic
and flow cytometric analysis revealed accumulation of the
Ub
 
G76V
 
-GFP and Ub-R-GFP reporters in cells expressing de-
 
tectable amounts of UBB
 
 
 
1
 
, whereas overexpression of
 
FLAG
 
Ub had no effect (Fig. 1 A). Flow cytometric analysis of
HeLa cells that accumulated the Ub
 
G76V
 
-GFP reporter re-
vealed a 60-fold increased fluorescence intensity (unpub-
lished data), compared with a 100-fold increase in the same
assay after treatment with potent inhibitors of the protea-
some (Dantuma et al., 2000b; Myung et al., 2001). It is
noteworthy that even though the vast majority of UBB
 
 
 
1
 
-
positive cells accumulated the Ub
 
G76V
 
-GFP reporter, the
percentage of fluorescent cells was 
 
 
 
1–2% of the total pop-
ulation, which is surprisingly low, as transfection efficiencies
between 20 and 40% were routinely obtained in these HeLa
cells (see below).
Kinetics of Ub
 
G76V
 
-GFP accumulation in UBB
 
 
 
1
 
-positive
cells showed that after 10 h, 
 
 
 
1/2 of the UBB
 
 
 
1
 
-expressing
cells had elevated levels of the Ub
 
G76V
 
-GFP proteasome sub-
strate, which further increased to 80% at 20 h posttransfec-
tion (Fig. 1 B). Thus, the expression of UBB
 
 
 
1
 
 preceded the
accumulation of GFP. Only background fluorescence was de-
tected in cells expressing 
 
FLAG
 
Ub (Fig. 1 B). In order to study
whether the elevated Ub
 
G76V
 
-GFP steady state levels are due
to delayed turnover of this proteasome substrate in response
to UBB
 
 
 
1
 
, we evaluated the clearance of the accumulated pro-
teasome substrate after blocking protein synthesis with cyclo-
heximide. We would like to emphasize that the cycloheximide
treatment will block not only the expression of Ub
 
G76V
 
-GFP,
but also of UBB
 
 
 
1
 
. To validate the experimental set up, we
first tested the clearance of Ub
 
G76V
 
-GFP from cells in which
the GFP substrate had been accumulated during a short incu-
bation with the reversible proteasome inhibitor MG132. In-
cubation with the proteasome inhibitor resulted in an 
 
 
 
10-
fold induction of GFP fluorescence. After removing MG132
and blocking protein synthesis with cycloheximide the cells
degraded the accumulated Ub
 
G76V
 
-GFP within 4 h (Fig. 1 C).
In sharp contrast, the mean fluorescence intensity of cells
transfected with UBB
 
 
 
1
 
 did not decline over a 6-h period, but
rather showed a modest increase. Although the percentage
GFP fluorescent cells declined in both the control and the
UBB
 
 
 
1
 
-transfected cells, after 6 h, we observed that only in
the UBB
 
 
 
1
 
-transfected cells was there still a substantial
amount of cells with accumulated Ub
 
G76V
 
-GFP (Fig. 1 D; un-
published data). These data show that the accumulated
Ub
 
G76V
 
-GFP has a prolonged half-life in cells transfected with
UBB
 
 
 
1
 
. The decrease of GFP fluorescent cells upon blockage
of protein synthesis in UBB
 
 
 
1
 
-transfected cells also suggests
that newly synthesized proteins are required to maintain a full
blockage on the ubiquitin/proteasome system.
Western blot analysis of UBB
 
 
 
1
 
-transfected HeLa and
SH-SY5Y cells revealed the presence of unmodified UBB
 
 
 
1
 
,
as well as three slower migrating bands (Fig. 1 E; unpub-
lished data). This pattern corresponds to that found in ear-
lier studies in which the bands were identified as conjugates
of UBB
 
 
 
1
 
 with one, two, or three ubiquitin moieties (Lam
et al., 2000; de Vrij et al., 2001).
 
Expression of UBB
 
 
 
1
 
 induces accumulation of 
polyubiquitinated proteins and cell cycle arrest
 
In subsequent experiments we analyzed the ubiquitination
status of accumulating proteasome substrates in UBB
 
 
 
1
 
-
expressing cells. Ub
 
G76V
 
-GFP HeLa cells were transiently
 
*Abbreviations used in this paper: GFP, green fluorescent protein(s);
nfGFP, nonfluorescent GFP; UFD, ubiquitin fusion degradation; Z-L
 
3
 
-VS,
carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone. 
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transfected with UBB
 
 
 
1
 
 and then sorted by flow cytometry
based on GFP fluorescence intensity. Western blots of ly-
sates from GFP-positive and -negative cells probed with an
anti-ubiquitin antibody demonstrated that elevated GFP
levels correlated with a general accumulation of polyubiqui-
tinated proteins (Fig. 2 A), corresponding to an approxi-
Figure 1. UBB
 1 inhibits the ubiquitin/proteasome pathway in vivo. (A) HeLa and SH-SY5Y cell lines stably expressing Ub
G76V-GFP or 
Ub-R-GFP were transfected with 
FLAGUb or UBB
 1. Cells were stained with an anti-FLAG or anti-UBB
 1 antibody and nuclei were counterstained 
with Hoechst 33258. Representative micrographs show expression of 
FLAGUb and UBB
 1 (left, red), fluorescence of Ub
G76V-GFP or Ub-R-GFP 
(middle, green), and counterstaining with Hoechst 33258 (right , blue). Bar, 20  m. (B) Ub
G76V-GFP HeLa cells were transfected with UBB
 1 
or 
FLAGUb harvested at indicated time points and analyzed by fluorescence microscopy. The results are expressed as percentage of UBB
 1- or 
FLAGUb-positive cells accumulating Ub
G76V-GFP. (C) Protein synthesis was blocked in Ub
G76V-GFP HeLa cells transfected with UBB
 1 by 
administration of 50  g/ml cycloheximide. As a control, cycloheximide was added to Ub
G76V-GFP HeLa cells in which the reporter had been 
accumulated by a 2.5-h treatment with the reversible proteasome inhibitor MG132. The mean fluorescence intensity of the GFP fluorescent 
population was determined at the indicated time points by flow cytometry. Mean fluorescence when cycloheximide was administrated was 
standardized as 100%. Triplicate values of representative experiment. (D) Flow cytometric analysis of Ub
G76V-GFP fluorescence in 
UBB
 1-transfected cells upon administration of cycloheximide at time points 0 and 6 h (as in C). Percentage GFP-positive cells and their 
mean fluorescence intensity are indicated. (E) Western blot analysis with an anti-UBB
 1 antibody of cell lysates of untransfected and UBB
 1 
transfected HeLa cells. Molecular mass marker and bands corresponding to UBB
 1 and ubiquitinated UBB
 1 are indicated. (*) Nonspecific 
immunoreactive bands. 
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mately twofold increase in the intensity of the smear of poly-
ubiquitin adducts (Fig. 2 B). Thus, UBB
 
 
 
1
 
 is likely to affect
an event downstream of polyubiquitination.
Impairment of the ubiquitin/proteasome system accom-
panied by the accumulation of polyubiquitinated proteins,
as observed in cells treated with inhibitors of the protea-
some, normally results in induction of apoptosis often pre-
ceded by arrest in the G2/M phase of the cell cycle (Lee
and Goldberg, 1998; Dantuma et al., 2000b). Therefore,
48 h posttransfection we analyzed the cell cycle distribu-
tion of UBB
 
 
 
1
 
-transfected Ub
 
G76V
 
-GFP HeLa cells emit-
ting background (Ub
 
G76V
 
-GFP
 
low
 
), moderately elevated
(Ub
 
G76V
 
-GFP
 
medium
 
) or high levels of GFP fluorescence
(Ub
 
G76V
 
-GFP
 
high
 
). Ub
 
G76V
 
-GFP
 
low
 
 cells displayed a cell cy-
cle distribution comparable to that of untransfected cells,
whereas a larger proportion of the Ub
 
G76V
 
-GFP
medium and
Ub
G76V-GFP
high cells were found in the G2/M phase,
which is indicative for cell cycle arrest (Fig. 2 C). A similar
G2/M arrest was observed in parental HeLa cells express-
ing UBB
 1, excluding the possibility that accumulation of
the GFP reporter may be responsible for the effect (Fig. 2
D). Within the time frame of our transient transfection,
we did not observe a significant increase of apoptotic cells
in the GFP positive populations.
UBB
 1 is a UFD substrate
To test whether physiological ubiquitination is required for the
inhibitory activity of UBB
 1 in vivo, we generated the mutant
UBB
 1/K48R in which the common ubiquitin conjugation site
Lys
48 was substituted with Arg. Surprisingly, UBB
 1/K48R was
still subject to ubiquitination in SH-SY5Y and HeLa cells (Fig.
3 A; unpublished data), suggesting that an alternate ubiquitina-
tion site may be used. Targeting of substrates for proteasomal
degradation may also occur via the less common ubiquitina-
tion site Lys
29. To date, this site has only been described for
UFD substrates in yeast in which both Lys
29 and Lys
48 of the
N-terminal ubiquitin moiety are targets for polyubiquitination
(Johnson et al., 1995; Koegl et al., 1999). Therefore, we com-
pared UBB
 1 mutants carrying Lys
29→Arg and Lys
48→Arg
substitutions. Indeed, both UBB
 1/K29R and UBB
 1/K48R were
equally efficiently ubiquitinated, whereas ubiquitin conjuga-
tion was virtually abrogated in the double mutant UBB
 1/
K29,48R (Fig. 3 A). Furthermore, substitution of either lysine res-
idue was sufficient to induce a significant increase in the steady
state levels of the mutant protein. The effect was most dramatic
with the UBB
 1/K29R mutant (Fig. 3 A), suggesting that this
ubiquitination site may preferentially target UBB
 1 for pro-
teasomal degradation. Surprisingly, we observed consistently
higher levels of UBB
 1/K29R as compared with UBB
 1/K29,48R in
both HeLa and neuroblastoma cells. Although we did not fully
understand this observation, subsequent analysis confirmed
that this is not due to proteasomal degradation of the double
mutant (Fig. 3 C; unpublished data).
Paradoxically, we observed that the UBB
 1 is a potent in-
hibitor of the ubiquitin/proteasome system, whereas proteins
carrying a UFD signal are normally rapidly degraded by the
proteasome (Johnson et al., 1992, 1995). As noted above, we
observed in transient transfections an unanticipated low per-
Figure 2. UBB
 1 induces accumulation 
of polyubiquitinated proteins and G2/M 
cell cycle arrest. (A) Ub
G76V-GFP HeLa 
cells were transfected with UBB
 1 and 
40,000 high fluorescent and 40,000 low 
fluorescent cells were sorted by flow 
cytometry 48 h posttransfection. Cell lysates 
of these populations were analyzed by 
Western blot probed with an anti-ubiquitin 
antibody. Molecular mass marker is 
indicated. (B) Quantitative analysis of anti-
ubiquitin immunoreactivity by densitome-
try from three independent experiments as 
described in A. (C) Flow cytometry analysis 
of Ub
G76V-GFP HeLa cells transiently trans-
fected with UBB
 1 on the left. The cell 
cycle distribution, analyzed by propidium 
iodide staining, of the Ub
G76V-GFP
high, 
Ub
G76V-GFP
medium, and Ub
G76V-GFP
low 
fluorescence are illustrated to the right. 
One representative experiment out of 
three. (D) Flow cytometric analysis of 
UBB
 1-transfected parental HeLa cells 
stained with an anti-UBB
 1 antibody (left). 
The cell cycle distribution of the UBB
 1-
positive and negative population is 
shown (right).Mutant ubiquitin inhibits proteasomal degradation | Lindsten et al. 421
centage of cells with detectable levels of the UBB
 1 protein.
This prompted us to investigate the possibility that the
UBB
 1 may be degraded in a fraction of the cells. To this end,
we constructed a plasmid in which UBB
 1 expression and
GFP expression are driven by the CMV and SV40 promotors,
respectively, which allowed us to identify all transfected cells
by the GFP fluorescence. Microscopic examination showed
that only  5% of the transfected cells expressed detectable
amounts of UBB
 1 (Fig. 3 B, top). Inclusion of the specific
proteasome inhibitor lactacystin (Fig. 3 B, bottom) or epoxo-
micin (unpublished data) resulted in accumulation of UBB
 1
in a great part of transfected cells. Western blot analysis con-
firmed the increase of UBB
 1 in response to lactacystin and
epoxomicin and showed that proteasomal degradation of
UBB
 1 was abrogated when Lys
29 and Lys
48 were substituted
with Arg residues (Fig. 3 C). Pulse-chase analysis of neuro-
blastoma cells transduced with a lentiviral vector encoding
UBB
 1 revealed that the UBB
 1 levels declined over the 3-h
period monitored, which is in line with the notion that
UBB
 1 is degraded in many cells (Fig. 3 D). These data, to-
gether with the experiment shown in Fig. 1, C and D, indi-
cate that whereas the fast majority of UBB
 1-expressing cells
turnover the mutant ubiquitin, it remains stable in a fraction
of the cells due to a general blockage of the ubiquitin/protea-
some system. Therefore, we conclude that UBB
 1 is an au-
thentic UFD substrate and degraded accordingly by the ubiq-
uitin/proteasome system in many cells.
Ubiquitination as a UFD substrate is required 
for a full inhibitory activity
Next, we tested whether ubiquitination at specific sites is re-
quired for the inhibitory activity of UBB
 1. UBB
 1 mutants
lacking the Lys
29, Lys
48, or both ubiquitination sites were
transiently transfected in SH-SY5Y cells expressing the GFP
reporters and the activity of the ubiquitin/proteasome sys-
tem was monitored by measuring GFP accumulation. Muta-
tion of both Lys
29 and Lys
48 abrogated the accumulation of
both GFP reporters in the neuroblastoma cells confirming
that ubiquitination is critical for the inhibitory effect (Fig. 4,
A and B). Surprisingly, substitutions of single lysine residues
had different effects on the degradation of UFD and N-end
rule substrates. The single lysine mutants UBB
 1/K29R and
UBB
 1/K48R were still able to inhibit the degradation of
Ub
G76V-GFP, although the inhibitory effect was strongly
compromised. In contrast, substitution of either lysine resi-
due was sufficient to fully abrogate the effect of UBB
 1 on
accumulation of the Ub-R-GFP reporter, demonstrating
that both ubiquitination sites are required to block the deg-
radation of N-end rule substrates. Thus, efficient inhibition
of the ubiquitin/proteasome system can only be accom-
plished by UBB
 1 containing both ubiquitination sites.
Lys
29 or Lys
48 residues can independently target an 
authentic UFD substrate for degradation
The intriguing finding that UBB
 1 needs both lysine residues
for optimal inhibitory activity brought up the question
whether these two ubiquitination sites act in concert or inde-
pendently in targeting substrates to the proteasome. This
question is difficult to address with UBB
 1, as the different
UBB
 1 mutants with lysine substitutions were shown to dif-
fer in their capacity to inhibit the proteasome; therefore,
changes in the turnover of these mutants can be due to target-
ing as well as inhibitory events. For this reason we turned to
the Ub
G76V-GFP reporter, which is a designed UFD substrate
Figure 3. UBB
 1 is a UFD substrate. 
(A) Western blot analysis with an anti-
UBB
 1 antibody of cell lysates from 
HeLa cells transfected with UBB
 1, 
UBB
 1/K29R, UBB
 1/K48R, UBB
 1/K29,48R. 
Products corresponding to unmodified 
and ubiquitinated UBB
 1 are indicated. 
(B) Micrographs of HeLa cells trans-
fected with pCMS-UBB
 1/GFP that were 
left untreated (top) or incubated for 16 h 
with 30  M lactacystin (bottom). Trans-
fected cells were identified by GFP 
expression (left) and transfected cells 
expressing detectable levels of UBB
 1 
were visualized by immunostaining 
(right). Bars, 100  m. (C) Western blot 
analysis with an anti-UBB
 1 antibody of 
the steady-state levels of UBB
 1 and 
UBB
 1/K29,48R in transiently transfected 
HeLa cells that were left untreated or 
incubated the proteasome inhibitors
lactacystin (30  M) or epoxomicin (500 
nM). (D) The turnover of UBB
 1 was 
determined by pulse-chase analysis in 
SK-N-SH neuroblastoma cells trans-
duced with lenti-UBB
 1. Intensity of the 
UBB
 1 band was quantified with a phos-
phoimager and the intensity at time point 
0 was standardized as 100%. (A–D) One 
representative experiment out of three.422 The Journal of Cell Biology | Volume 157, Number 3, 2002
that allows easy evaluation of proteasomal degradation (Dan-
tuma et al., 2000b). We used a previously described flow cy-
tometric assay in which HeLa cells were transiently trans-
fected with the different Ub
G76V-GFP mutants and the
percentage of GFP fluorescent cells in the absence or presence
of the proteasome inhibitor carboxybenzyl-leucyl-leucyl-leu-
cine vinyl sulfone (Z-L3-VS; Bogyo et al., 1997) was deter-
mined (Dantuma et al., 2000a). Substitution of both Lys
29
and Lys
48 residues in Ub
G76V-GFP completely abrogated pro-
teasomal degradation of the GFP reporter (Fig. 5, A and B),
confirming that these two lysines are the sole ubiquitination
sites targeting for degradation. We observed that substitution
of Lys
29 resulted in a partial stabilization, whereas removal of
Lys
48 did not stabilize the protein. These data show that each
of these two ubiquitin trees can function as an autonomous
signal that target a model UFD substrate to the proteasome.
Yet, similar to the situation in yeast (Johnson et al., 1995;
Koegl et al., 1999), the Lys
29 tree appears to be more effective
than Lys
48 in targeting a UFD for degradation.
Enhancement of the UFD signal strengthens 
the inhibitory activity of UBB
 1
Because UBB
 1 is a target as well as an inhibitor of the ubiq-
uitin/proteasome system, we asked whether the inhibitory ac-
tivity could be reversed by modifications that may enhance its
degradation. UFD signals can be turned into a more potent
degradation signal by introducing multiple tandem organized
uncleavable ubiquitin moieties (Stack et al., 2000). Therefore,
we inserted one or two additional uncleavable ubiquitin (Ub*)
moieties at the N terminus of UBB
 1 and generated the Ub*–
UBB
 1 and Ub*2-UBB
 1 constructs (Fig. 6 A). However, un-
expectedly, enhancement of the UFD signal did not result in
accelerated turnover of UBB
 1, as reported with other UFD
substrates (Stack et al., 2000), but instead a dramatic accumu-
Figure 4. Inhibitory activity of UBB
 1 
requires ubiquitination at Lys
29 and Lys
48. 
(A) Micrographs of Ub
G76V-GFP (left) 
and Ub-R-GFP SH-SY5Y cells (right) 
transfected with UBB
 1, UBB
 1/K29R, 
UBB
 1/K48R, or UBB
 1/K29,48R. The cells 
were stained for UBB
 1 (left) and
analyzed for GFP fluorescence (right). 
Bars, 100  m. (B) Quantification of three 
independent experiments as shown in A. 
The results are expressed as the percent 
of the UBB
 1 expressing cells with 
accumulated Ub
G76V-GFP or Ub-R-GFP 
levels.Mutant ubiquitin inhibits proteasomal degradation | Lindsten et al. 423
lation of UBB
 1 was observed (Fig. 6 B). The effect was most
apparent with Ub*2-UBB
 1,
 in which in addition high-molec-
ular mass species were observed in the stacking gel, implying
that polyubiquitin trees are conjugated to UBB
 1.
Next, we compared the effect of UBB
 1, Ub*–UBB
 1,
and the Ub*2-UBB
 1 on proteasomal degradation in HeLa
and SH-SY5Y cells. In line with the positive correlation be-
tween the number of N-terminal ubiquitin moieties and the
amounts of UBB
 1, Ub–UBB
 1, or Ub*2-UBB
 1 accumulat-
ing in transfected cells, we found a dose-dependent correlation
between the number of ubiquitin moieties and the accumula-
tion of Ub
G76V-GFP in HeLa cells (Fig. 6 C) and Ub
G76V-GFP
and Ub-R-GFP in SH-SY5Y cells (unpublished data). Thus,
targeting for ubiquitin-/proteasome-dependent degradation is
crucial for the inhibitory activity of UBB
 1, and enhancement
of its degradation signal paradoxically increases its stability and
strengthens its inhibitory activity resulting in a more severe in-
hibition of proteasomal degradation.
No impaired proteasomal degradation in response to 
overexpression of other substrates
A possible explanation for the inhibitory activity of UBB
 1 is
that overexpression of proteasome substrates will saturate the
system and competitively affect degradation of the Ub-R-GFP
and Ub
G76V-GFP substrates. To address this issue, we de-
signed substrates whose expression was driven by the CMV
promotor similar to the UBB
 1 constructs. These substrates
were 
FLAGUb-R-nfGFP and 
FLAGUb
G76V-nfGFP, which are
based on a nonfluorescent variant of GFP (nfGFP), and
FLAGp53. Ub
G76V-GFP HeLa cells expressing the substrate
were identified by the FLAG tag present on each of the sub-
strates. Microscopic and flow cytometric analysis demon-
strated that only UBB
 1 was able to block degradation of the
GFP substrate, whereas none of the other three substrates had
an effect on Ub
G76V-GFP levels (Fig. 7). It is noteworthy that
even the nonfluorescent variant of the Ub
G76V-GFP substrate
itself did not induce accumulation. Hence, the inhibitory ef-
fect of UBB
 1 is not simply due to saturating the ubiquitin/
proteasome system by overexpression of a substrate.
Discussion
In the present study we show that an abnormal component
of the ubiquitin/proteasome system, which has been de-
tected in a broad variety of neurodegenerative diseases, can
Figure 5. Lys
29 and Lys
48 can independently target a UFD substrate 
for degradation. (A) Dot plots of flow cytometric analysis of HeLa 
cells transiently transfected with GFP, Ub
G76V-GFP, Ub
K29R/G76V-GFP, 
Ub
K48R/G76V-GFP, and Ub
K29,48R/G76V-GFP. Half of the cells were left 
untreated and the other half was incubated for 16 h with 10  M of 
the proteasome inhibitor Z-L3-VS. The percentage GFP-positive cells 
and the ratio between the percentage of fluorescent cells in samples 
untreated/inhibitor-treated are indicated. (B) Quantification of three 
independent experiments as shown in A. Values significantly differ-
ent from the Ub
G76V-GFP sample are marked with asterisks (t test,
P   0.05). Mean   SD of three independent experiments. Ratios  1 
indicate proteasomal degradation of the protein.
Figure 6. Targeting UBB
 1 for proteasomal degradation enhances its inhibitory effect. (A) Schematic 
illustration of the UBB
 1, Ub*–UBB
 1, and Ub*2-UBB
 1 constructs. (B) Western blot analysis with anti-
UBB
 1 antibody of cell lysates of HeLa cells transfected with UBB
 1, Ub*–UBB
 1, Ub*2-UBB
 1. 
Molecular mass marker and bands corresponded to unmodified and ubiquitinated UBB
 1 proteins as well 
as high molecular mass UBB
 1 are indicated. (C) Flow cytometric analysis of GFP fluorescence of Ub
G76V-
GFP HeLa cells transfected with UBB
 1, Ub*–UBB
 1, and Ub*2-UBB
 1. The percentage of cells with 
accumulated GFP and the mean fluorescence intensity of this population are indicated at the bottom.424 The Journal of Cell Biology | Volume 157, Number 3, 2002
inhibit proteasomal degradation in neuronal cells. Interest-
ingly, all the pathologic conditions for which expression of
UBB
 1 has been described, including several tauopathies
and a polyglutamine disorder, are characterized by the ac-
cumulation of insoluble deposits formed by aggregated
proteins (Sherman and Goldberg, 2001). Under normal
conditions, misfolded proteins are efficient substrates of
ubiquitin-/proteasome-dependent proteolysis, and a key
question has been the nature of the primary events that fa-
vors their accumulation rather than rapid clearance in af-
fected neurons. Our data show that UBB
 1 is a powerful in-
hibitor of this proteolytic pathway in vivo. The effect was
sufficient to induce cell cycle arrest at the G2/M boundary,
at least under the conditions of overexpression achieved in
our transient transfection assays. A particularly important as-
pect of our findings is the demonstration that UBB
 1 is not
only an inhibitor, but also a target of the ubiquitin/protea-
some system. Interestingly, it has been shown that whereas
UBB
 1 transcripts are present in both normal and affected
brains, the protein product has only been detected in af-
fected neurons of individuals suffering from neurodegenera-
tive disorders (unpublished data). Notably, we observed that
only a small population of the transfected cells expressed de-
tectable levels of the UBB
 1 protein followed by accumula-
tion of the GFP substrates, whereas the majority of the cells
destroy the UBB
 1 by proteasomal degradation. Using an
adenovirus based transduction method in neurons, which
accomplishes massive expression of UBB
 1, and an in vitro
degradation assay, it was recently shown that UBB
 1 is a
rather stable and toxic protein (de Vrij et al., 2001). Con-
ceivably, the ubiquitin/proteasome system can cope with
low levels of UBB
 1 but accelerated proteasomal target-
ing, by elevated steady-state levels or by enhancement of
the UFD signal, obstructs ubiquitin-/proteasome-dependent
proteolysis of this aberrant ubiquitin. Alternatively, the cells
that accumulate UBB
 1 and the GFP substrates have a sub-
optimal ubiquitin/proteasome system, making them more
sensitive to the inhibitory effect of UBB
 1. We envision that
in vivo slight changes in the efficiency of proteolysis, as may
be achieved in selected neurons by the production of  -amy-
loid peptide in Alzheimer’s disease (Gregori et al., 1995;
Keller et al., 2000), or the formation of insoluble aggregates
in polyglutamine disorders (Bence et al., 2001; Jana et al.,
2001), may be sufficient to initiate a process resulting in ac-
cumulation of UBB
 1 that will eventually lead to cellular in-
toxication by a general inhibition of the ubiquitin/protea-
some system and ultimately to cell death.
Detailed analysis of the requirements for the inhibitory ef-
fect of UBB
 1 revealed some unexpected characteristics. It
was acknowledged earlier that UBB
 1, even though it cannot
be conjugated to substrates (van Leeuwen et al., 1998), can
serve as a recipient for polyubiquitination.Therefore, it was
postulated that polyubiquitinated UBB
 1, similar to free
polyubiquitin trees (Piotrowski et al., 1997), can block pro-
teolysis of proteasome substrates (Lam et al., 2000). Indeed,
we confirm that ubiquitination of UBB
 1 is required for its
inhibitory activity in vivo. However, several lines of evidence
argue that ubiquitinated UBB
 1 does not simply act as a free
polyubiquitin tree but is instead an aberrant UFD substrate.
First, we show that UBB
 1 is ubiquitinated both at Lys
29 and
Lys
48, a pattern that is unique for UFD substrates (Johnson et
al., 1995; Koegl et al., 1999). Second, UBB
 1 is structurally
similar to a UFD substrate, as it has an N-terminal uncleav-
able ubiquitin moiety linked to a C-terminal extension.
Third, our data clearly demonstrate that UBB
 1 is degraded
by the proteasome in a large number of the transfected cells.
Even though the related UFD reporter Ub
G76V-GFP seems
to be susceptible to inhibition by UBB
 1 with a single ubiq-
uitination site to some extent, blockage of degradation of the
Ub-R-GFP reporter required the Lys
29 as well as Lys
48 resi-
dues. One possible explanation is that the pool of inhibitory
UBB
 1 consists of molecules bearing two ubiquitin trees.
Binding of both trees to acceptor sites in the proteasome may
be required to achieve interactions sufficiently tight to pre-
vent access to other polyubiquitinated substrates. It is note-
worthy that in the crystal structure of ubiquitin the Lys
29 and
Figure 7. Overexpression of other 
proteasome substrates does not inhibit 
turnover of Ub
G76V-GFP. Ub
G76V-GFP 
HeLa cells were transiently transfected 
with UBB
 1, 
FLAGUb
G76V-nfGFP, 
FLAGUb-
R-nfGFP and 
FLAGp53. UBB
 1 transfected 
cells were stained with the anti-UBB
 1 
antibody while the nonfluorescent 
FLAGUb
G76V-nfGFP and 
FLAGUb-R-nfGFP 
constructs and 
FLAGp53 were stained with 
a FLAG-specific antibody. Representative 
micrographs of the immunostaining (left, 
red), the Ub
G76V-GFP fluorescence 
(middle, green), and the Hoechst 33258 
counterstaining (right, blue) are shown. 
Note that as expected the 
FLAGUb
G76V-
nfGFP and 
FLAGUb-R-nfGFP give a 
homogenous staining in the cytosol and 
nucleus, whereas 
FLAGp53 is localized 
in the nucleus. To the left are shown 
flow cytometric analysis of the GFP 
fluorescence upon transfection with 
the different constructs.Mutant ubiquitin inhibits proteasomal degradation | Lindsten et al. 425
Lys
48 residues are localized on opposite faces of the molecule
and would structurally allow double ubiquitin trees (Cook et
al., 1994). It is also possible that the two sites act coopera-
tively in optimizing ubiquitination, as suggested by the re-
cent finding that in yeast the polyubiquitination factor E4/
UFD2 requires Lys
48 in a UFD signal in order to accommo-
date efficient polyubiquitination at Lys
29 (Koegl et al., 1999).
Interestingly, a recombination event in the gene encoding the
murine homologue of E4/UFD2 may underlie the delayed
Wallerian nerve degeneration observed in a mouse strain
(Conforti et al., 2000). The experiments with the Ub
G76V-
GFP substrate strongly support the model based on a tight
interaction between UBB
 1 bearing two ubiquitin trees and
the proteasome, as both lysine residues can independently
target this model UFD substrate to the proteasome, suggest-
ing that Lys
29 and Lys
48 can each bear a functional ubiquitin
tree. Several studies suggest that the rate of polyubiquitina-
tion determines the duration of the interaction between a
substrate and the proteasome (Lam et al., 1997; Thrower et
al., 2000), and it is likely that regardless of whether these two
lysine residues are required for the formation of double ubiq-
uitin trees or more efficient polyubiquitination at Lys
29, the
outcome is a polyubiquitinated UBB
 1 that cannot be rap-
idly released from the proteasome. The combination of a
tightly bound but poorly degradable proteasome substrate
may clog the system by obstructing access to other substrates,
especially when the UBB
 1 feed in large amounts to the pro-
teasome. It is tempting to speculate that in its short C-termi-
nal extension may lie the reason for the inhibitory activity of
UBB
 1, either because it is too short to allow efficient tether-
ing of the recruited UBB
 1 into the cavity of the proteasome
as has been proposed for another UFD substrate with a short
extension (Johnson et al., 1992), or due to the presence of
specific residues that stabilize the structure and hamper un-
folding (Lee et al., 2001). Notably, during the revision of this
manuscript, it was reported that introduction of stable struc-
tures within a proteasome substrate can turn an otherwise
normal substrate into a potent inhibitor (Navon and Gold-
berg, 2001). An alternative possibility is that UBB
 1 inter-
feres more dramatically with degradation of the Ub
G76V-GFP
substrate because these proteins are both UFD substrates and
may well be targets for the same ubiquitin ligase. Accord-
ingly, the stabilized UBB
 1 may competitively inhibit the
ubiquitination of Ub
G76V-GFP.
Our model deviates from an earlier presented model that
proposed poor deubiquitination of UBB
 1 as a possible
cause for inhibition of the ubiquitin/proteasome system. Al-
though we show that UBB
 1 can indeed inhibit the protea-
some in vivo, and that this inhibitory activity relies on ubiq-
uitination of UBB
 1, in accordance with the in vitro data
(Lam et al., 2000), our results warrant a reevaluation of
some of the observations in this earlier study. In the light of
our results it is not surprising that ubiquitinated UBB
 1 is
less efficiently disassembled than free polyubiquitin trees
by isoT, considering that this deubiquitination enzyme is
highly specific for free polyubiquitin trees rather then ubiq-
uitinated substrates (Wilkinson et al., 1995). It will be inter-
esting to compare in a similar deubiquitination assay if
UBB
 1 is also more refractory to deubiquitination when
compared with an authentic UFD substrate. The length de-
pendence of the ubiquitin tree is another puzzling aspect.
We confirmed that the bulk of UBB
 1 in cell lysates con-
tains one, two, or at most three conjugated ubiquitin moi-
eties, whereas in the in vitro assay, UBB
 1 with synthetically
linked Lys
48 tetraubiquitin was used, which fulfill much bet-
ter the minimal length requirement for inhibitory polyubiq-
uitin (Thrower et al., 2000). However, the interaction be-
tween substrates simultaneously ubiquitinated at Lys
29 and
Lys
48 and the proteasome is not well understood, and it is
possible that with these unique trees UBB
 1 can interact
with the proteasome while bearing only a limited number of
ubiquitins.
The critical significance of the UFD nature of UBB
 1 is
further emphasized by the finding that introduction of mul-
tiple UFD signals had a dramatic enhancing effect on its in-
hibitory activity. Contrary to what we had expected on the
basis of previously reported data (Stack et al., 2000), addi-
tion of one or two uncleavable ubiquitin moieties resulted in
further accumulation of UBB
 1 and a stronger inhibition of
the ubiquitin/proteasome system. Thus, in line with the hy-
pothesis that cells can cope only with a certain level of ubiq-
uitinated UBB
 1, when this level is increased by accelerating
targeting UBB
 1 starts to accumulate and further inhibits its
own degradation. The inhibitory activity of UBB
 1 may
then establish a destructive feedback loop, which may ulti-
mately result in overall inhibition of the ubiquitin/protea-
some system.
In conclusion, we have provided evidence that UBB
 1 acts
as a potent inhibitor of the ubiquitin/proteasome system in
neuronal cells, and we have uncovered some important fea-
tures of its mechanism of action. It remains to be seen
whether and under what conditions this impaired proteoly-
sis contributes to the generation of the protein aggregates
that characterize many UBB
 1-associated pathologies. Fi-
nally, of paramount importance will be the identification of
factors that can override the inhibitory effect of UBB
 1.
Materials and methods
Plasmid construction
All UBB
 1 and ubiquitin open reading frames were expressed from a CMV
promoter in the mammalian expression vectors pcDNA3 (Invitrogen), pBK-
CMV (Stratagene), EGFP-N1, or pCMS-EGFP (CLONTECH Laboratories,
Inc.). The FLAG-tagged ubiquitin construct, 
FLAGUb, was generated by PCR
amplification of ubiquitin from UBB
 1 and subsequent in-frame ligation
into a FLAG-containing vector. Construction of the modified UBB
 1 con-
structs Ub*–UBB
 1 and
 Ub*2-UBB
 1 was based on a UBB
 1 plasmid in
which an NheI site was introduced in between the ubiquitin moiety
and the  1 extension of UBB
 1 (this also introduced a D79S amino acid
substitution, although that did not affect its inhibitory capacity). The
UBB
 1(NheI) was digested with NheI, and PCR-amplified Ub
G76V was li-
gated between the ubiquitin moiety and  1 extension. This procedure was
repeated once to generate the Ub*2-UBB
 1 construct. Lys to Arg substitu-
tions in the different constructs were introduced by PCR amplification.
nfGFP was constructed by introducing the amino acids substitution Y67R
in the chromophore of GFP using PCR amplification. 
FLAGUb
G76V-nfGFP,
FLAGUb-R-nfGFP, and 
FLAGp53 were generated by insertion of a double
stranded oligonucleotide encoding the FLAG epitope as described previ-
ously (Heessen et al., 2002).
Transfections and tissue culture
The human cervical epithelial carcinoma line HeLa and neuroblastoma
cell line SH-SY5Y were cultured in Iscove’s modified Eagle’s medium and
high-glucose Dulbecco’s modified Eagle medium, respectively, supple-
mented with 10% fetal calf serum (Life Technologies), 10 U/ml penicillin,426 The Journal of Cell Biology | Volume 157, Number 3, 2002
and 10  g/ml streptomycin. HeLa and SH-SY5Y cells were transiently
transfected with Lipofectamine (Life Technologies) and calcium phosphate
method, respectively. Cells were analyzed 48 h posttransfection unless
stated otherwise. Stably transfected cell lines were selected in the presence
of 0.5 mg/ml geneticin (Sigma-Aldrich) and screened for GFP fluorescence
upon administration of proteasome inhibitors. Where indicated transfected
cells were treated the reversible proteasome inhibitor MG132 (Affinity) or
the irreversible proteasome inhibitors lactacystin, epoxomicin (Affinity) or
Z-L3-VS, a gift from Dr. Hidde Ploegh (Harvard Medical School, Boston,
MA) (Bogyo et al., 1997)
Western blot analysis
Cell lysates were fractionated on SDS-PAGE and transferred to Protan BA 85
nitrocellulose filters (Schleicher & Schuell). The filters were blocked in PBS
supplemented with 5% skim milk and 0.1% Tween-20, were and incubated
with rabbit polyclonal antibody specific to UBB
 1 (Ubi-3, 050897; van
Leeuwen et al., 1998), ubiquitin (Dako), or GFP (Molecular Probes). After
subsequent washings and incubation with peroxidase-conjugated goat anti–
rabbit serum, the blots were developed by enhanced chemiluminiscence
(ECL; Amersham Pharmacia Biotech). Quantification of Western blot bands
was performed by densitometry (Molecular Dynamics).
Pulse-chase analysis
Neuroblastoma cells, SK-N-SH, were cultured and differentiated with reti-
noic acid. Differentiated SK-N-SH cells were transfected with a lentiviral-
based vector (Naldini et al., 1996), containing the UBB
 1 open reading
frame (lenti-UBB
 1). 24–48 h after transduction, cells were incubated in
medium lacking methionine and cysteine for 1 h, and were subsequently
metabolically labeled by incubating them with medium containing 100
 Ci Tran35S-label for 4 h. After the labeling period, medium was replaced
by Dulbecco’s modified Eagle medium with 10% FCS medium. Cells were
washed, chased with culture medium, and harvested at the indicated time
points in 10 mM Tris, 0.15 M NaCl, 0.1% NP40, 0.1% Triton X-100, 20
mM EDTA, pH 8.0 buffer containing 0.1% SDS and protease inhibitors.
UBB
 1 was immunoprecipitated overnight at 4 C with anti-UBB
 1 anti-
body Ubi-3 (1:1,000), and protein-A Sepharose beads were added to the
UBB
 1 infected cell lysates. Analysis and quantification of the pulse-chase
experiments were performed with the usage of a phosphoimager and the
software package Imagequant software.
Fluorescence microscopy and flow cytometry
For fluorescence microscopy, the cells were grown and transfected on
coverslips. After rinsing in PBS and fixation in 4% paraformaldehyde, im-
munostaining was performed using an anti-UBB
 1 rabbit polyclonal anti-
body or anti-FLAG mouse monoclonal antibody (M5; Sigma-Aldrich). After
subsequent washing steps with PBS, cells were incubated with the second-
ary antibodies labeled Alexa Fluor 594 (Molecular Probes) or Texas red
(Dako). All antibodies were diluted in 50 mM Tris, pH 7.4, 0.9% NaCl,
0.25% gelatine, and 0.5% Triton X-100. Cells were counterstained with
Hoechst 33258 (Molecular Probes). Fluorescence was analyzed using a
LEITZ-BMRB fluorescence microscope (Leica) and images were captured
with a Hamamatsu cooled CCD camera. For quantitative analysis, 100–
200 UBB
 1 or 
FLAGUb-positive cells per sample were scored for GFP fluo-
rescence. Flow cytometry was performed with a FACSort flow cytometer
(Becton Dickinson) and data were analyzed with CellQuest software. For
analysis of cell cycle distribution, cells were harvested 2 d post transfec-
tion and fixed in 1% paraformaldehyde. After two washings in PBS, the
cells were permeabilized with 70% ethanol and then incubated with pro-
pidium iodide. Flow cytometric analysis of the stability of Ub
G76V-GFP mu-
tants was performed as described before (Dantuma et al., 2000a).
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